Close Menu

Alzheimer's disease

The grant, which was awarded under the NIH Pathway to Independence program, will fund research into the genetics of Alzheimer's disease.

In Cell this week: blood immune cell changes in COVID-19 patients and spatial transcriptomics in Alzheimer's disease.

Broad and One Mind scientists will use single-cell RNA sequencing technologies to investigate the role of microglia in Alzheimer's disease onset and progression.

Blood Marker, Maybe

New studies suggest levels of a blood protein that may reflect whether someone has Alzheimer's disease.

Roche, Shionogi, Janssen Pharmaceuticals, and Eisai will provide the charity with specimens from Alzheimer's disease patients who participated in clinical studies.

The Phase 2 grant is for work the company is doing to analyze the proteomic responses of immune cells in patients with Alzheimer's and related conditions.

In PLOS this week: transcriptomics-based strategy to study Alzheimer's disease heterogeneity, insecticide resistance diversity and evolution, and more.

The company's adaptive low-resource testing technology requires no instrumentation and limited equipment, making it adaptable to settings without clinical lab infrastructure.

The study also found that certain genes may influence multiple complex traits, while others only affect one phenotype, making them worthwhile therapeutic targets.

The charity also announced a partnership with Sage Bionetworks to establish an online repository for biomarker data generated by grant recipients.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.